NEW YORK (GenomeWeb News) – The National Heart, Lung, and Blood Institute has awarded a consortium of institutions $14.4 million to research better methods of predicting which hypertrophic cardiomyopathy patients are at the highest risk of heart failure or sudden death.

The University of Virginia School of Medicine and the University of Oxford in the UK, will direct the five-year study which will follow 2,750 patients for up to five years. The study will be conducted at 35 to 40 sites in the US, Canada, and Europe, including the UK, Italy and Germany.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.